Skip to main content

Table 2 Analysis of the risk factors for HA-AKI

From: Acute kidney injury in hospitalized patients with nonexacerbated chronic obstructive pulmonary disease

 

Univariate model

Multivariate model

OR

95% CI

P value

OR

95% CI

P value

Increased age

1.899

1.324–2.724

0.001

1.463

1.003–2.134

0.048

Female

1.558

1.212–2.002

0.001

1.498

1.149–1.952

0.003

Cor pulmonale

1.830

1.431–2.339

< 0.001

1.790

1.379–2.324

< 0.001

CKD

  

< 0.001

  

< 0.001

 Stage 1–2

Reference

  

Reference

  

 Stage 3a

1.775

1.163–2.708

0.008

1.754

1.136–2.709

0.011

 Stage 3b

3.139

1.862–5.292

< 0.001

3.161

1.850–5.401

< 0.001

 Stage 4

6.478

3.532–11.882

< 0.001

6.575

3.531–12.243

< 0.001

Diabetes

1.357

1.045–1.762

0.022

Not entered in final model

Clinical medication

 Proton pump inhibitors

1.142

0.910–1.434

0.253

Not selected

 Diuretics/dehydrants

1.950

1.547–2.459

< 0.001

1.527

1.193–1.954

0.001

 RAS inhibitors

1.081

0.841–1.389

0.544

Not selected

 NSAIDs

0.967

0.723–1.293

0.821

Not selected

 Intravenous diodones

1.928

1.436–2.588

< 0.001

2.048

1.499–2.798

< 0.001

 Intravenous hemostatics

0.927

0.632–1.359

0.697

Not selected

 Aminoglycosides

1.256

0.769–2.053

0.362

Not selected

 Glycopeptides

4.141

2.469–6.944

< 0.001

3.991

2.322–6.859

< 0.001

  1. HA-AKI hospital acquired-acute kidney injury; CKD chronic kidney disease; RAS renin-angiotensin system; NSAIDs nonsteroidal anti-inflammatory drugs
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us